X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Reprocell will provide support for Lantern Pharma's Phase 2 trial of LP-300 (tavocept) in combination with carboplatin and pemetrexed in patients who are never smokers with lung adenocarcinoma and have relapsed after treatment with TKIs.
Lead Product(s): Dimesna,Pemetrexed,Carboplatin
Therapeutic Area: Oncology Product Name: LP-300
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Lantern Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 03, 2023
Details:
REPROCELL's IBD culture studies have dynamically informed the potential of the HT-003 therapeutic platform, including focusing future development on lead candidate molecules with optimized target responses for ulcerative colitis and Crohn's disease.
Lead Product(s): HT-003
Therapeutic Area: Gastroenterology Product Name: HT-003
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Hoth Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 19, 2021
Details:
Fresh explants of ulcerative colitis and Crohn's disease tissues obtained from surgical resection will be used as the test systems to investigate the therapeutic potential of the HT-003 drugs via measurement of key biomarkers for these diseases.
Lead Product(s): HT-003
Therapeutic Area: Gastroenterology Product Name: HT-003
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hoth Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 11, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
